Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)
Leukemia & Lymphoma | August 12, 2004 | Volume: 45 | Issue: 10 | Pages: 2047-2055
10.1080/10428190410001714043
| PMID 15370249